Sertindole

Sertindole

Clinical data
Trade names	Serdolect, Serlect
AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: C
Routes of administration	By mouth
ATC code	N05AE03 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	75%[1]
Protein binding	99.5%[1]
Metabolism	Liver (mostly via CYP2D6 and CYP3A4)[2][3]
Elimination half-life	3 days[2]
Excretion	Faecal (the majority), Kidney (4% metabolites; 1% unchanged)[2]
Identifiers
IUPAC name 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one
CAS Number	106516-24-9 Y
PubChem CID	60149
IUPHAR/BPS	98
DrugBank	DB06144 Y
ChemSpider	54229 Y
UNII	GVV4Z879SP
KEGG	D00561 Y
ChEBI	CHEBI:9122 Y
ChEMBL	ChEMBL12713 Y
CompTox Dashboard (EPA)	DTXSID6048967
ECHA InfoCard	100.162.562
Chemical and physical data
Formula	C24H26ClFN4O
Molar mass	440.95 g·mol−1
3D model (JSmol)	Interactive image
SMILES Fc1ccc(cc1)n3c2ccc(Cl)cc2c(c3)C5CCN(CCN4C(=O)NCC4)CC5
InChI InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31) Y Key:GZKLJWGUPQBVJQ-UHFFFAOYSA-N Y
(verify)

Sertindole, sold under the brand name Serdolect among others, is an antipsychotic medication. Sertindole was developed by the Danish pharmaceutical company Lundbeck and marketed under license by Abbott Labs. Like other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative.

Sertindole is not approved for use in the United States and was discontinued in Australia in January 2014.^{[citation needed]}